Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 22438073)

1.

Mammographic breast density and breast cancer risk by menopausal status, postmenopausal hormone use and a family history of breast cancer.

Yaghjyan L, Colditz GA, Rosner B, Tamimi RM.

Cancer Causes Control. 2012 May;23(5):785-90. doi: 10.1007/s10552-012-9936-7. Epub 2012 Mar 23.

2.

Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics.

Yaghjyan L, Colditz GA, Collins LC, Schnitt SJ, Rosner B, Vachon C, Tamimi RM.

J Natl Cancer Inst. 2011 Aug 3;103(15):1179-89. doi: 10.1093/jnci/djr225. Epub 2011 Jul 27.

3.

Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to the time since the mammogram.

Yaghjyan L, Colditz GA, Rosner B, Tamimi RM.

Cancer Epidemiol Biomarkers Prev. 2013 Jun;22(6):1110-7. doi: 10.1158/1055-9965.EPI-13-0169. Epub 2013 Apr 19.

4.

Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones.

Tworoger SS, Missmer SA, Barbieri RL, Willett WC, Colditz GA, Hankinson SE.

J Natl Cancer Inst. 2005 Apr 20;97(8):595-602.

5.

Mammographic breast density and breast cancer risk: interactions of percent density, absolute dense, and non-dense areas with breast cancer risk factors.

Yaghjyan L, Colditz GA, Rosner B, Tamimi RM.

Breast Cancer Res Treat. 2015 Feb;150(1):181-9. doi: 10.1007/s10549-015-3286-6. Epub 2015 Feb 13.

6.

High volumetric breast density predicts risk for breast cancer in postmenopausal, but not premenopausal, Korean Women.

Park IH, Ko K, Joo J, Park B, Jung SY, Lee S, Kwon Y, Kang HS, Lee ES, Lee KS, Ro J.

Ann Surg Oncol. 2014 Dec;21(13):4124-32. doi: 10.1245/s10434-014-3832-1. Epub 2014 Jun 17.

PMID:
24934582
7.

Polymorphisms in steroid hormone pathway genes and mammographic density.

Haiman CA, Hankinson SE, De Vivo I, Guillemette C, Ishibe N, Hunter DJ, Byrne C.

Breast Cancer Res Treat. 2003 Jan;77(1):27-36.

PMID:
12602902
8.

Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use.

Kerlikowske K, Cook AJ, Buist DS, Cummings SR, Vachon C, Vacek P, Miglioretti DL.

J Clin Oncol. 2010 Aug 20;28(24):3830-7. doi: 10.1200/JCO.2009.26.4770. Epub 2010 Jul 19.

9.

Plasma adiponectin concentrations and risk of incident breast cancer.

Tworoger SS, Eliassen AH, Kelesidis T, Colditz GA, Willett WC, Mantzoros CS, Hankinson SE.

J Clin Endocrinol Metab. 2007 Apr;92(4):1510-6. Epub 2007 Jan 9.

PMID:
17213279
10.

Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women.

Tamimi RM, Byrne C, Colditz GA, Hankinson SE.

J Natl Cancer Inst. 2007 Aug 1;99(15):1178-87. Epub 2007 Jul 24.

11.

Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States).

Vachon CM, Kuni CC, Anderson K, Anderson VE, Sellers TA.

Cancer Causes Control. 2000 Aug;11(7):653-62.

PMID:
10977110
12.

The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.

Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE.

N Engl J Med. 1995 Jun 15;332(24):1589-93.

13.

+331G/A variant in the progesterone receptor gene, postmenopausal hormone use and risk of breast cancer.

Kotsopoulos J, Tworoger SS, De Vivo I, Hankinson SE, Hunter DJ, Willett WC, Chen WY.

Int J Cancer. 2009 Oct 1;125(7):1685-91. doi: 10.1002/ijc.24477. Erratum in: Int J Cancer. 2009 Nov 15;125(10):2487. DeVivo, Immaculata [corrected to De Vivo, Immaculata].

14.

Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women.

Tamimi RM, Hankinson SE, Chen WY, Rosner B, Colditz GA.

Arch Intern Med. 2006 Jul 24;166(14):1483-9.

PMID:
16864758
15.

Endogenous sex hormones, prolactin and mammographic density in postmenopausal Norwegian women.

Bremnes Y, Ursin G, Bjurstam N, Rinaldi S, Kaaks R, Gram IT.

Int J Cancer. 2007 Dec 1;121(11):2506-11.

PMID:
17657735
16.

Premenopausal endogenous steroid hormones and breast cancer risk: results from the Nurses' Health Study II.

Fortner RT, Eliassen AH, Spiegelman D, Willett WC, Barbieri RL, Hankinson SE.

Breast Cancer Res. 2013 Mar 6;15(2):R19. doi: 10.1186/bcr3394.

17.

Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.

MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk.

Breast Cancer Res Treat. 2010 Jan;119(2):463-74. doi: 10.1007/s10549-009-0407-0. Epub 2009 May 8. Erratum in: Breast Cancer Res Treat. 2010 Jan;119(2):475.

PMID:
19424794
18.

Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy.

Kerlikowske K, Zhu W, Hubbard RA, Geller B, Dittus K, Braithwaite D, Wernli KJ, Miglioretti DL, O'Meara ES; Breast Cancer Surveillance Consortium.

JAMA Intern Med. 2013 May 13;173(9):807-16. doi: 10.1001/jamainternmed.2013.307.

19.

Association between common risk factors and molecular subtypes in breast cancer patients.

Turkoz FP, Solak M, Petekkaya I, Keskin O, Kertmen N, Sarici F, Arik Z, Babacan T, Ozisik Y, Altundag K.

Breast. 2013 Jun;22(3):344-50. doi: 10.1016/j.breast.2012.08.005. Epub 2012 Sep 14.

PMID:
22981738
20.

Use of postmenopausal hormones, alcohol, and risk for invasive breast cancer.

Chen WY, Colditz GA, Rosner B, Hankinson SE, Hunter DJ, Manson JE, Stampfer MJ, Willett WC, Speizer FE.

Ann Intern Med. 2002 Nov 19;137(10):798-804.

PMID:
12435216
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk